Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Apr 14;40(5):148.
doi: 10.1007/s12032-023-01989-9.

Cryopreventive temperatures prior to chemotherapy

A Ibrahim  1 , E Camci  2 , L Khairallah  2 , M Jontell  3 , J Walladbegi  2
Affiliations
Randomized Controlled Trial

Cryopreventive temperatures prior to chemotherapy

A Ibrahim et al. Med Oncol. .

Abstract

The superiority of oral cryotherapy (OC) for prevention of chemotherapy-induced oral mucositis (OM) has been demonstrated in several trials. In clinical settings, cooling is usually initiated prior to the chemotherapy infusion. It then continues during the infusion, and for a period after the infusion has been completed. While the cooling period post-infusion depends on the half-life of the chemotherapeutic drug, there is no consensus on when cooling should be initiated prior to the infusion. The lowest achieved temperature in the oral mucosa is believed to provide the best condition for OM prevention. Given this, it was of interest to investigate when along the course of intraoral cooling this temperature is achieved. In total, 20 healthy volunteers participated in this randomized crossover trial. Each subject attended three separate cooling sessions of 30 min each, with ice chips (IC) and the intraoral cooling device (ICD) set to 8 and 15 °C, respectively. At baseline and following 5, 10, 15, 20 and 30 min of cooling, intraoral temperatures were registered using a thermographic camera. The greatest drop in intraoral temperature was seen after 5 min of cooling with IC, ICD8°C and ICD15°C, respectively. A statistically significant difference, corresponding to 1.4 °C, was seen between IC and the ICD15°C (p < 0.05). The intraoral temperature further declined throughout the 30 min of cooling, showing an additional temperature reduction of 3.1, 2.2, and 1.7 °C for IC, ICD8°C and ICD15°C, respectively.

Keywords: Cryotherapy; Intraoral cooling device; Oral mucositis; Tolerability.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Fig. 1
Fig. 1
The Cooral® System. a schematic illustration of the intraoral cooling device; b the portable thermostat unit. Reprinted and modified with permission from Walladbegi J., Gellerstedt M., Svanberg A., Jontell M. Innovative intraoral cooling device better tolerated and equally effective as ice cooling. Cancer Chemother Pharmacol. 2017 Nov; 80(5):965–72. (http://creativecommons.org/licenses/by/4.0/)
Fig. 2
Fig. 2
Intraoral mucosal temperatures at baseline and following 5, 10, 15, 20, and 30 min of cooling with ice chips (IC), and the intraoral cooling device (ICD) set to 8 and 15 °C, respectively
Fig. 3
Fig. 3
The difference in intraoral mucosal temperature reduction between 5 and 30 min of cooling within each cooling method, ice chips (IC), intraoral cooling device (ICD) set to 8 and 15 °C, respectively. ***p ≤ .001
Fig. 4
Fig. 4
Intraoral temperatures for risk surfaces, i.e., right, and left buccal mucosae, upper and lower labial mucosae at baseline and following 5, 10, 15, 20, and 30 min of cooling with ice chips (IC), and the intraoral cooling device (ICD) set to 8 and 15 °C, respectively
See this image and copyright information in PMC

References

    1. Kanagalingam J, Wahid MIA, Lin JC, Cupino NA, Liu E, Kang JH, et al. Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study. Support Care Cancer. 2018;26(7):2191–2200. doi: 10.1007/s00520-018-4050-3. - DOI - PubMed
    1. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14(6):505–515. doi: 10.1007/s00520-006-0055-4. - DOI - PubMed
    1. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–2713. doi: 10.1002/cncr.23898. - DOI - PubMed
    1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277–284. doi: 10.1038/nrc1318. - DOI - PubMed
    1. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009;45(12):1015–1020. doi: 10.1016/j.oraloncology.2009.08.006. - DOI - PubMed

Publication types

LinkOut - more resources